Rosenberg Matthew Hamilton Grows Position in Abbott Laboratories $ABT

Rosenberg Matthew Hamilton increased its position in shares of Abbott Laboratories (NYSE:ABT) by 14.1% in the second quarter, Holdings Channel.com reports. The firm owned 2,010 shares of the healthcare product maker’s stock after purchasing an additional 248 shares during the quarter. Rosenberg Matthew Hamilton’s holdings in Abbott Laboratories were worth $273,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Hughes Financial Services LLC purchased a new stake in Abbott Laboratories in the 1st quarter valued at about $27,000. Abound Financial LLC purchased a new stake in Abbott Laboratories in the 1st quarter valued at about $28,000. Elequin Capital LP purchased a new stake in Abbott Laboratories in the 1st quarter valued at about $30,000. JCIC Asset Management Inc. purchased a new stake in Abbott Laboratories in the 1st quarter valued at about $32,000. Finally, Vision Financial Markets LLC purchased a new stake in Abbott Laboratories in the 1st quarter valued at about $33,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Abbott Laboratories Trading Down 2.9%

NYSE ABT opened at $129.35 on Thursday. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25. The firm has a market cap of $225.13 billion, a PE ratio of 16.21, a price-to-earnings-growth ratio of 2.53 and a beta of 0.69. The company has a 50 day moving average price of $132.59 and a 200 day moving average price of $131.60. Abbott Laboratories has a 52 week low of $110.86 and a 52 week high of $141.23.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Wednesday, October 15th. The healthcare product maker reported $1.30 EPS for the quarter, hitting the consensus estimate of $1.30. The firm had revenue of $11.37 billion during the quarter, compared to analyst estimates of $11.40 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. Abbott Laboratories’s revenue was up 6.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.21 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. As a group, sell-side analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be paid a dividend of $0.59 per share. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.8%. Abbott Laboratories’s dividend payout ratio is presently 29.57%.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the company’s stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the transaction, the chief financial officer owned 51,003 shares in the company, valued at approximately $6,862,453.65. This represents a 9.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.46% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on ABT shares. Morgan Stanley boosted their price objective on shares of Abbott Laboratories from $127.00 to $137.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 15th. Weiss Ratings restated a “buy (b)” rating on shares of Abbott Laboratories in a report on Wednesday, October 8th. Raymond James Financial reduced their price target on shares of Abbott Laboratories from $142.00 to $141.00 and set an “outperform” rating for the company in a report on Friday, July 18th. The Goldman Sachs Group boosted their price target on shares of Abbott Laboratories from $153.00 to $157.00 and gave the company a “buy” rating in a report on Wednesday, October 1st. Finally, Royal Bank Of Canada boosted their price target on shares of Abbott Laboratories from $145.00 to $147.00 and gave the company an “outperform” rating in a report on Tuesday, July 15th. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average target price of $146.17.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.